Graham Collins, Associate Professor of Hematology at the Oxford Cancer and Hematology Center shared a post on X:
“Starglo – EHA2024 plenary:
- R-GemOx vs. Glofit-GemOx R/R DLBCL
- 2L (SCT-ineligible) / 3L+
- OS primary EP
- Med OS 12.9 months (con) vS 25.5 months
- More TEAEs but more Rx exposure
- More deaths but mainly COVID
- G1/2 CRS as expected
A practice-changing study. ”
Source: Graham Collins/X
